z-logo
Premium
Combined immunophenotyping and in situ hybridization (FICTION): a rapid method to study cell lineage involvement in myelodysplastic syndromes
Author(s) -
SOENEN VALERIE,
FENAUX PIERRE,
FLACTIF MARTIAL,
LEPELLEY PASCALE,
LAI JEAN LUC,
COSSON ALAIN,
PREUDHOMME CLAUDE
Publication year - 1995
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1995.tb05604.x
Subject(s) - immunophenotyping , lineage (genetic) , myelodysplastic syndromes , in situ hybridization , cell lineage , medicine , pathology , immunology , biology , bone marrow , genetics , antigen , cellular differentiation , gene , gene expression
Summary. We present a study in which we used a recently described method combining fluorescence in situ hybridization (FISH) and immunophenotyping, i.e. FICTION, to assess the involvement of different cell lineages in myelodysplastic syndrome (MDS) with monosomy 7 (–7), trisomy 8 (+8) or loss of Y chromosome (–Y). Blood or marrow smears or cytocentrifuge preparations were stained both by antibodies to granulocytes (CD 15 ), monocytes (CD 14 ), T lymphocytes (CD 3 ), B lymphocytes (CD 2 o) and by probes specific for chromosomes 7, 8 or Y. Of nine cases of MDS with –7, four with +8 and two with – Y studied, none showed lymphocytic involvement by the chromosome abnormality. In contrast, ‐7,‐1‐8 and – Y were found in granulocytes and monocytes in all patients studied, but they involved a variable proportion of those cells. The partial involvement by –7 and +8 seen in some cases suggests that myelopoi'esis was only partially clonal in those cases, or that the chromosome abnormality was a secondary event in the MDS process. FICTION therefore appears to be a simple and easily reproducible method that can be used for the assessment of lineage involvement in MDS and other haematological malignancies.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here